Litcius/Paper detail

A Case Report of Non-Bacterial Cystitis Caused by Immune Checkpoint Inhibitors

Sihui Zhu, Lijuan Bian, Jia Lv, Baorui Liu, Jie Shen

2021Frontiers in Immunology16 citationsDOIOpen Access PDF

Abstract

We report a case of non-bacterial cystitis after treatment with programmed death-1 (PD-1) and programmed cell death-ligand 1 (PD-L1) antibodies, which was considered an immune-related adverse event (irAE). A 48-year-old male patient with intrahepatic cholangiocarcinoma (ICC) was treated with nivolumab after postoperative multi-line treatment. This patient recurred worsening of psoriasis and repeated urinary tract discomfort. The drug was discontinued and surgery was performed due to the recurrence of the tumor suggested by imaging. After receiving three cycles of chemotherapy treatment combined with atezolizumab, urinary tract discomfort reappeared. No bacteria were found in multiple urine cultures, and non-bacterial bladder inflammation was considered after cystoscopy biopsy. This is a report of non-bacterial inflammation of the urinary tract caused by immunotherapy.

Topics & Concepts

MedicineNivolumabCystoscopyUrinary systemAtezolizumabImmunotherapyInflammationAdverse effectImmune systemInternal medicineUrologySurgeryGastroenterologyImmunologyBladder and Urothelial Cancer TreatmentsCancer Immunotherapy and BiomarkersPolyomavirus and related diseases
A Case Report of Non-Bacterial Cystitis Caused by Immune Checkpoint Inhibitors | Litcius